Skip to main content

Advertisement

SpringerLink
Log in

An approach to diagnosis and management of patients with pyoderma gangrenosum from an international perspective: results from an expert forum

  • RESEARCH LETTER
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Afifi L, Ortega-Loayza AG, Shinkai K (2020) Management of classic ulcerative pyoderma gangrenosum. Cutis 106(3):119–123. https://doi.org/10.12788/cutis.0076

    Article  PubMed  Google Scholar 

  2. Alavi A, French LE, Davis MD, Brassard A, Kirsner RS (2017) Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment. Am J Clin Dermatol 18(3):355–372. https://doi.org/10.1007/s40257-017-0251-7

    Article  PubMed  Google Scholar 

  3. Dissemond J, Marzano AV, Hampton PJ, Ortega-Loayza AG (2023) Pyoderma gangrenosum: treatment options. Drugs 83(14):1255–1267. https://doi.org/10.1007/s40265-023-01931-3

    Article  PubMed  PubMed Central  Google Scholar 

  4. Maverakis E, Le ST, Callen J, Wollina U, Marzano AV, Wallach D, Schadt C, Martinez-Alvarado YC, Cheng MY, Ma C, Merleev A, Ormerod A, Craig F, Jockenhöfer F, Dissemond J, Salva K, Williams HC, Fiorentino D (2019) New validated diagnostic criteria for pyoderma gangrenosum. J Am Acad Dermatol 80(4):87–88. https://doi.org/10.1016/j.jaad.2018.08.068

    Article  Google Scholar 

  5. Pimentel MA, Li MM, Noe MH, Latour E, Seminario-Vidal L, Greiling T, Shinkai K, Hamilton A, Alavi A, Bolognia JL, Cowen EW, Dominguez A, Fernandez AP, Fivenson D, Huang WW, Madigan LM, Mauskar M, Means AD, Nelson CA, Patsatsi A, Ortega-Loayza AG (2023) Features that define clinical severity of ulcerative pyoderma gangrenosum: a Delphi consensus study of experts and patients on behalf of the US medical dermatology society. Br J Dermatol 188(4):566–568. https://doi.org/10.1093/bjd/ljac137

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine, Oregon Health and Science University, Portland, OR, USA

    Olivia M. Haddadin

  2. Department of Dermatology, Oregon Health and Science University, Portland, OR, 97239, USA

    Alex G. Ortega-Loayza

  3. Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

    Angelo Valerio Marzano

  4. Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy

    Angelo Valerio Marzano

  5. Department of Dermatology, Mayo Clinic, Rochester, MN, USA

    Mark Denis P. Davis & Afsaneh A. Alavi

  6. Department of Dermatology, University of Pisa, Pisa, Italy

    Valentina Dini

  7. Department of Dermatology, Venerology and Allergology, University of Essen, Essen, Germany

    Joachim Dissemond

  8. Department of Dermatology, The Royal Victoria Infirmary, Newcastle Upon Tyne, UK

    Philip J. Hampton

  9. Newcastle Biomedical Research Centre, Newcastle Upon Tyne, UK

    Philip J. Hampton

  10. Department of Dermatology and Department of Biomedical Engineering, University Hospital of Basel, Basel, Switzerland

    Alexander A. Navarini

  11. Dermatology Clinic, Wolfson Medical Center, Holon, Israel

    Eran Shavit

  12. The Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel

    Eran Shavit

  13. Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan

    Yayoi Tada

  14. Department of Dermatology, Fukushima Medical University, Fukushima, Japan

    Toshiyuki Yamamoto

Authors
  1. Olivia M. Haddadin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alex G. Ortega-Loayza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angelo Valerio Marzano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mark Denis P. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Valentina Dini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joachim Dissemond
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Philip J. Hampton
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alexander A. Navarini
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Eran Shavit
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yayoi Tada
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Toshiyuki Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Afsaneh A. Alavi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Author OMH wrote the main manuscript text, prepared the tables, led investigation and participated in project administration and methodology. Author AGOL participated in review and editing, was responsible for the project conceptualization, contributed to methodology, and was co-chair of the WCD 2023 PG Expert Forum session. Author AA participated in review and editing, contributed to methodology, and was chair of the WCD 2023 PG Expert Forum session. Author AVM participated in review and editing, contributed to methodology, and was cochair of the WCD 2023 PG Expert Forum session. Authors MDPD, VD, JD, PJH, AAN, ES, YT, and TY participated in review and editing.

Corresponding author

Correspondence to Alex G. Ortega-Loayza.

Ethics declarations

Competing interests

AGOL is the current President of the Pacific Dermatology Association and serves as an associate editor for Dermatology (Karger). Additionally, he is a consultant for Genentech and Guidepoint and an advisor to Bristol Meyer Squibb, Boehringer Ingelheim and Janssen. Dr. Ortega has received research grants from the Lilly, Janssen, Incyte and Pfizer. He is supported by NIH NIAMS R01 AR083110. AVM reports consultancy/advisory boards disease-relevant honoraria from AbbVie, Boehringer-Ingelheim, Novartis, Pfizer, Sanofi, Janssen and UCB. VD reports consultancy with Abbvie, Novartis, Eli Lilly, Almirall, UCB, Sanofi, Jansenn. JD reports consultancy/advisory boards disease-relevant honoraria from Boehringer-Ingelheim, InflaRx, Novartis, Janssen and UCB. AAN declares being a consultant and advisor and/or receiving speaking fees/grants and/or served as an investigator in clinical trials for AbbVie, Almirall, Amgen, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, GlaxoSmithKline, LEO Pharma, Janssen-Cilag, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, Sanofi, Serono and UCB. YT reports research grants, honoraria from Eisai, Abbvie and Novartis. AA is the board member of HS foundation and a consultant for Abbvie, Almirall, BI, Kymera, InflaRx, Incyte, Novartis, UCB. All other authors declare no competing interests.

Conflict of interest

AGOL is the current President of the Pacific Dermatology Association and serves as an associate editor for Dermatology (Karger). In addition, he is a consultant for Genentech and Guidepoint and an advisor to Bristol Meyer Squibb, Boehringer Ingelheim and Janssen. Dr. Ortega has received research grants from the Lilly, Janssen, Incyte, and Pfizer. He is supported by NIH NIAMS R01 AR083110. AVM reports consultancy/advisory boards disease-relevant honoraria from AbbVie, Boehringer Ingelheim, Novartis, Pfizer, Sanofi, Janssen and UCB. VD reports consultancy with Abbvie, Novartis, Eli Lilly, Almirall, UCB, Sanofi, Jansenn. JD reports consultancy/advisory boards disease-relevant honoraria from Boehringer Ingelheim, InflaRx, Novartis, Janssen, and UCB. AAN declares being a consultant and advisor and/or receiving speaking fees/grants and/or served as an investigator in clinical trials for AbbVie, Almirall, Amgen, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, GlaxoSmithKline, LEO Pharma, Janssen-Cilag, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, Sanofi, Serono, and UCB. YT reports research grants, honoraria from Eisai, Abbvie and Novartis. AA is the board member of HS foundation and a consultant for Abbvie, Almirall, BI, Kymera, InflaRx, Incyte, Novartis, UCB. All other authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 351 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Haddadin, O.M., Ortega-Loayza, A.G., Marzano, A.V. et al. An approach to diagnosis and management of patients with pyoderma gangrenosum from an international perspective: results from an expert forum. Arch Dermatol Res 316, 89 (2024). https://doi.org/10.1007/s00403-024-02829-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00403-024-02829-0

Search

Navigation